Overview

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

Status:
Recruiting
Trial end date:
2024-10-15
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Janssen Research & Development, LLC
Momenta Pharmaceuticals, Inc.